1.A Case Report of Polyarteritis Nodosa in Small Bowel.
Phil Lip LEE ; Jong Hyun KIM ; Hee Wook KIM ; Dae Sung YOON ; Samuel LEE ; Jae Jeung LEE ; Cheul Jae PARK ; Eun Sook NAM ; Ho Cheul KIM ; Ja Young LEE ; Jong Hyuck KIM ; Jae Young YOO
Journal of the Korean Surgical Society 1998;55(3):440-446
Polyatreritis nodosa is a rare autoimmune disease (the immune system attacking its own body) characterized by spontaneous inflammation of the arteries (arteritis) of the body. Because arteries are involved, the disease can affect any organ of the body. The most common areas of involvement include the muscles, joints, intestines (bowels), nerves, kidneys, and skin. Gastrointestinal involvement is reported in about 50% of the cases, but bleeding complications are rare and result in a poor prognosis. Polyarteritis nodosa is most common in middle-age persons. Recently, we experienced polyarteritis nodosa which presented as small bowel bleeding and which was diagnosed by angiography, a small-bowel series, and patholgic examination of the surgically removed ileum specimen. We report this case with a brief review of the literature.
Angiography
;
Arteries
;
Autoimmune Diseases
;
Hemorrhage
;
Humans
;
Ileum
;
Immune System
;
Inflammation
;
Intestines
;
Joints
;
Kidney
;
Muscles
;
Polyarteritis Nodosa*
;
Prognosis
;
Skin
2.Dermatologic Diseases Associated with Atopic Dermatitis in Koreans: Multicenter Study.
Hye In LEE ; Tae Young HAN ; Seong Jun SEO ; Do Won KIM ; Myeung Nam KIM ; Moon Bum KIM ; Il Hwan KIM ; Young Suck RO ; Young Lip PARK ; Young Min PARK ; Chun Wook PARK ; Phil Seung SEO ; Hee Joon YU ; Moo Hyung LEE ; Seung Churl LEE ; Ai Young LEE ; Yang Won LEE ; Sang Hyun CHO ; So Yun CHO ; Jong Soo CHOI ; Seon Wook HWANG
Korean Journal of Dermatology 2010;48(3):191-197
BACKGROUND: Dermatological diseases can occur with atopic dermatitis. OBJECTIVE: The purpose of this study was to analyze diseases associated with atopic dermatitis in Koreans. METHODS: From November, 2007, to May, 2008, 948 patients with atopic dermatitis who visited the department of dermatology at 19 hospitals were evaluated for associated diseases. RESULTS: Of 948 patients, 53.8% (510) had symptoms associated with other dermatological diseases. In order of frequency, diseases associated with atopic dermatitis included acne, hand/foot eczema, seborrheic dermatitis, urticaria, warts, and recurrent herpes simplex. The number of associated diseases did not change significantly with the severity of atopic dermatitis. However, the incidence of hand/foot eczema and eczema herpeticum correlated significantly with the severity of atopic dermatitis. CONCLUSION: There is a distinct pattern of diseases associated with atopic dermatitis in Koreans.
Acne Vulgaris
;
Dermatitis, Atopic
;
Dermatitis, Seborrheic
;
Dermatology
;
Eczema
;
Herpes Simplex
;
Humans
;
Incidence
;
Kaposi Varicelliform Eruption
;
Methylmethacrylates
;
Polystyrenes
;
Urticaria
;
Warts
3.Consensus Guidelines for the Treatment of Atopic Dermatitis in Korea (Part II): Systemic Treatment.
Jung Eun KIM ; Hyun Jeong KIM ; Bark Lynn LEW ; Kyung Ho LEE ; Seung Phil HONG ; Yong Hyun JANG ; Kui Young PARK ; Seong Jun SEO ; Jung Min BAE ; Eung Ho CHOI ; Ki Beom SUHR ; Seung Chul LEE ; Hyun Chang KO ; Young Lip PARK ; Sang Wook SON ; Young Jun SEO ; Yang Won LEE ; Sang Hyun CHO ; Chun Wook PARK ; Joo Young ROH
Annals of Dermatology 2015;27(5):578-592
BACKGROUND: Since the treatment guidelines for atopic dermatitis (AD) were issued by the Korean Atopic Dermatitis Association (KADA) work group in 2006, there have been further advances in the systemic treatment of AD. OBJECTIVE: We aimed to establish updated evidence- and experience-based systemic treatment guidelines for Korean AD. METHODS: We compiled a database of references from relevant systematic reviews and guidelines regarding the systemic management of AD, including antihistamines, antimicrobials, systemic immunomodulators, allergen-specific immunotherapy, phototherapy, adjunctive treatment, and complementary and alternative medicines. Evidence for each statement was graded and classified based on the strength of the recommendation. Thirty-nine council members of KADA participated in the three rounds of votes and expert consensus recommendations were established. RESULTS: The use of antihistamines is recommended to relieve pruritus and to prevent exacerbation due to scratching in AD patients. Infection should be controlled as needed and long-term medication should be avoided. For moderate to severe AD patients, concomitant active treatments with systemic immunomodulators are indicated. Cyclosporine is the first choice among systemic immunomodulators and others should be considered as second-line alternatives. Allergen-specific immunotherapy could be effective in AD patients with aeroallergen hypersensitivity. Phototherapy can be useful for moderate to severe AD patients and narrow-band ultraviolet B is the most effective option. Complementary and alternative medicines cannot be recommended for treating AD. CONCLUSION: We expect these recommendations to be a reference guide for physicians and AD patients in choosing the appropriate treatment to improve quality of life and decrease unnecessary social medical costs.
Consensus*
;
Cyclosporine
;
Dermatitis
;
Dermatitis, Atopic*
;
Histamine Antagonists
;
Humans
;
Hypersensitivity
;
Immunologic Factors
;
Immunotherapy
;
Korea*
;
Phototherapy
;
Pruritus
;
Quality of Life
4.Consensus Guidelines for the Treatment of Atopic Dermatitis in Korea (Part I): General Management and Topical Treatment.
Jung Eun KIM ; Hyun Jeong KIM ; Bark Lynn LEW ; Kyung Ho LEE ; Seung Phil HONG ; Yong Hyun JANG ; Kui Young PARK ; Seong Jun SEO ; Jung Min BAE ; Eung Ho CHOI ; Ki Beom SUHR ; Seung Chul LEE ; Hyun Chang KO ; Young Lip PARK ; Sang Wook SON ; Young Jun SEO ; Yang Won LEE ; Sang Hyun CHO ; Chun Wook PARK ; Joo Young ROH
Annals of Dermatology 2015;27(5):563-577
BACKGROUND: Since the treatment guidelines for atopic dermatitis (AD) were released by the Korean Atopic Dermatitis Association (KADA) work group in 2006, there have been several advances in AD management. OBJECTIVE: We aimed to establish updated evidence- and experience-based treatment guidelines for Korean AD. METHODS: We collected a database of references from relevant systematic AD reviews and guidelines regarding general AD management such as bathing and skin care, avoidance of exacerbating factors, education and psychosocial support, and the use of moisturizers and topical anti-inflammatory and antipruritic drugs. Evidence for each statement was graded and the strength of the recommendation for each statement classified. Thirty-nine KADA council members participated in three rounds of voting to establish an expert consensus of recommendations. RESULTS: Basic AD treatment includes proper bathing and skin care, avoidance of exacerbating factors, proper education and psychosocial support, and use of moisturizers. The regular use of moisturizer has a steroid-sparing effect and reduces relapse episodes. The short- and long-term use of topical corticosteroids and calcineurin inhibitors improves AD symptoms and should be encouraged to use in an active and proactive treatment. Wet-wrap therapy can be used for rapid recovery of acute exacerbation. Topical antipruritic drugs cannot be recommended for the treatment of AD. CONCLUSION: This report provides up-to-date evidence- and experience-based treatment guidelines for AD regarding general management and topical treatment. In addition, the average agreement scores obtained by a panel of experts based on the Korean healthcare system and patient adherence are presented.
Adrenal Cortex Hormones
;
Antipruritics
;
Baths
;
Calcineurin
;
Consensus*
;
Delivery of Health Care
;
Dermatitis, Atopic*
;
Education
;
Korea*
;
Patient Compliance
;
Politics
;
Recurrence
;
Skin Care
5.Consensus Guidelines for the Treatment of Atopic Dermatitis in Korea (Part II): Systemic Treatment.
Jung Eun KIM ; Hyun Jeong KIM ; Bark Lynn LEW ; Kyung Ho LEE ; Seung Phil HONG ; Yong Hyun JANG ; Kui Young PARK ; Seong Jun SEO ; Jung Min BAE ; Eung Ho CHOI ; Ki Beom SUHR ; Seung Chul LEE ; Hyun Chang KO ; Young Lip PARK ; Sang Wook SON ; Young Jun SEO ; Yang Won LEE ; Sang Hyun CHO ; Chun Wook PARK ; Joo Young ROH
Annals of Dermatology 2015;27(5):578-592
BACKGROUND: Since the treatment guidelines for atopic dermatitis (AD) were issued by the Korean Atopic Dermatitis Association (KADA) work group in 2006, there have been further advances in the systemic treatment of AD. OBJECTIVE: We aimed to establish updated evidence- and experience-based systemic treatment guidelines for Korean AD. METHODS: We compiled a database of references from relevant systematic reviews and guidelines regarding the systemic management of AD, including antihistamines, antimicrobials, systemic immunomodulators, allergen-specific immunotherapy, phototherapy, adjunctive treatment, and complementary and alternative medicines. Evidence for each statement was graded and classified based on the strength of the recommendation. Thirty-nine council members of KADA participated in the three rounds of votes and expert consensus recommendations were established. RESULTS: The use of antihistamines is recommended to relieve pruritus and to prevent exacerbation due to scratching in AD patients. Infection should be controlled as needed and long-term medication should be avoided. For moderate to severe AD patients, concomitant active treatments with systemic immunomodulators are indicated. Cyclosporine is the first choice among systemic immunomodulators and others should be considered as second-line alternatives. Allergen-specific immunotherapy could be effective in AD patients with aeroallergen hypersensitivity. Phototherapy can be useful for moderate to severe AD patients and narrow-band ultraviolet B is the most effective option. Complementary and alternative medicines cannot be recommended for treating AD. CONCLUSION: We expect these recommendations to be a reference guide for physicians and AD patients in choosing the appropriate treatment to improve quality of life and decrease unnecessary social medical costs.
Consensus*
;
Cyclosporine
;
Dermatitis
;
Dermatitis, Atopic*
;
Histamine Antagonists
;
Humans
;
Hypersensitivity
;
Immunologic Factors
;
Immunotherapy
;
Korea*
;
Phototherapy
;
Pruritus
;
Quality of Life
6.Consensus Guidelines for the Treatment of Atopic Dermatitis in Korea (Part I): General Management and Topical Treatment.
Jung Eun KIM ; Hyun Jeong KIM ; Bark Lynn LEW ; Kyung Ho LEE ; Seung Phil HONG ; Yong Hyun JANG ; Kui Young PARK ; Seong Jun SEO ; Jung Min BAE ; Eung Ho CHOI ; Ki Beom SUHR ; Seung Chul LEE ; Hyun Chang KO ; Young Lip PARK ; Sang Wook SON ; Young Jun SEO ; Yang Won LEE ; Sang Hyun CHO ; Chun Wook PARK ; Joo Young ROH
Annals of Dermatology 2015;27(5):563-577
BACKGROUND: Since the treatment guidelines for atopic dermatitis (AD) were released by the Korean Atopic Dermatitis Association (KADA) work group in 2006, there have been several advances in AD management. OBJECTIVE: We aimed to establish updated evidence- and experience-based treatment guidelines for Korean AD. METHODS: We collected a database of references from relevant systematic AD reviews and guidelines regarding general AD management such as bathing and skin care, avoidance of exacerbating factors, education and psychosocial support, and the use of moisturizers and topical anti-inflammatory and antipruritic drugs. Evidence for each statement was graded and the strength of the recommendation for each statement classified. Thirty-nine KADA council members participated in three rounds of voting to establish an expert consensus of recommendations. RESULTS: Basic AD treatment includes proper bathing and skin care, avoidance of exacerbating factors, proper education and psychosocial support, and use of moisturizers. The regular use of moisturizer has a steroid-sparing effect and reduces relapse episodes. The short- and long-term use of topical corticosteroids and calcineurin inhibitors improves AD symptoms and should be encouraged to use in an active and proactive treatment. Wet-wrap therapy can be used for rapid recovery of acute exacerbation. Topical antipruritic drugs cannot be recommended for the treatment of AD. CONCLUSION: This report provides up-to-date evidence- and experience-based treatment guidelines for AD regarding general management and topical treatment. In addition, the average agreement scores obtained by a panel of experts based on the Korean healthcare system and patient adherence are presented.
Adrenal Cortex Hormones
;
Antipruritics
;
Baths
;
Calcineurin
;
Consensus*
;
Delivery of Health Care
;
Dermatitis, Atopic*
;
Education
;
Korea*
;
Patient Compliance
;
Politics
;
Recurrence
;
Skin Care
7.Consensus Update for Systemic Treatment of Atopic Dermatitis
Ji Hyun LEE ; Jung Eun KIM ; Gyeong-Hun PARK ; Jung Min BAE ; Ji Yeon BYUN ; Min Kyung SHIN ; Tae Young HAN ; Seung Phil HONG ; Yong Hyun JANG ; Hye One KIM ; Chan Ho NA ; Bark-Lynn LEW ; JiYoung AHN ; Chang Ook PARK ; Young-Joon SEO ; Yang Won LEE ; Sang Wook SON ; Eung Ho CHOI ; Young Lip PARK ; Joo Young ROH
Annals of Dermatology 2021;33(6):497-514
Background:
In 2015, the Korean Atopic Dermatitis Association (KADA) working group published consensus guidelines for treating atopic dermatitis (AD).
Objective:
We aimed to provide updated consensus recommendations for systemic treatment of AD in South Korea based on recent evidence and experience.
Methods:
We compiled a database of references from relevant systematic reviews and guidelines on the systemic management of AD. Evidence for each statement was graded and classified based on thestrength of the recommendation. Forty-two council members from the KADA participated in three rounds of voting to establish a consensus on expert recommendations.
Results:
We do not recommend long-term treatment with systemic steroids forpatients with moderate-to-severe AD due to the risk of adverse effects. We recommend treatment with cyclosporine or dupilumab and selective treatment with methotrexate or azathioprine for patients with moderate-to-severe AD. We suggest treatment with antihistamines as an option for alleviating clinical symptoms of AD. We recommend selective treatment with narrowband ultraviolet B for patients with chronic moderate-to-severe AD. We do not recommend treatment with oral antibiotics for patients with moderate-to-severe AD but who have no signs of infection. We did not reach a consensus on recommendations for treatment with allergen-specific immunotherapy, probiotics, evening primrose oil, orvitamin D for patients with moderate-to-severe AD. We also recommend educational interventions and counselling for patients with AD and caregivers to improve the treatment success rate.
Conclusion
We look forward to implementing a new and updated consensus of systemic therapy in controlling patients with moderate-to-severe AD.